TFP5, a Peptide Derived from Cdk5 Activator p35, Protects Pancreatic β Cells from Glucose Toxicity

Area of Science:

• Biochemistry
• Cell Biology
• Endocrinology

Background:

• Cyclin-dependent kinase 5 (Cdk5) hyperactivity is implicated in type 2 diabetes mellitus (T2DM) pathogenesis.
• Pancreatic β-cell dysfunction and inflammation contribute to T2DM progression.

Purpose of the Study:

• To synthesize and evaluate the therapeutic potential of TFP5, a novel peptide inhibitor of Cdk5, for T2DM.
• To investigate TFP5's effects on Cdk5 activity, insulin secretion, β-cell apoptosis, and pancreatic islet inflammation in vitro and in vivo.

Main Methods:

• TFP5 synthesized by conjugating peptide p5 (p35 protein derivative) with FITC and TAT domain.
• MIN6 cells (mouse islet β cells) treated with varying glucose concentrations (5 or 25 mM).
• In vivo studies conducted on C57BL/6J (control) and db/db (T2DM) mice.

Main Results:

• TFP5 effectively inhibited pathological Cdk5 hyperactivity.
• TFP5 enhanced insulin secretion and protected pancreatic β cells from apoptosis.
• TFP5 reduced inflammatory cytokine expression (TGF-β1, TNFα, IL-1β) in pancreatic islets.

Conclusions:

• TFP5 demonstrates significant therapeutic potential for T2DM by targeting Cdk5.
• TFP5 exhibits protective effects on pancreatic β cells and reduces islet inflammation.
• TFP5 represents a promising novel therapeutic candidate for type 2 diabetes mellitus.